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Abstract
G protein coupled receptor 55 (GPR55) is expressed throughout the body, and although its exact physiological function is
unknown, studies have suggested a role in the cardiovascular system. In particular, GPR55 has been proposed as mediating
the haemodynamic effects of a number of atypical cannabinoid ligands; however this data is conflicting. Thus, given the
incongruous nature of our understanding of the GPR55 receptor and the relative paucity of literature regarding its role in
cardiovascular physiology, this study was carried out to examine the influence of GPR55 on cardiac function. Cardiac
function was assessed via pressure volume loop analysis, and cardiac morphology/composition assessed via histological
staining, in both wild-type (WT) and GPR55 knockout (GPR552/2) mice. Pressure volume loop analysis revealed that basal
cardiac function was similar in young WT and GPR552/2 mice. In contrast, mature GPR552/2 mice were characterised by
both significant ventricular remodelling (reduced left ventricular wall thickness and increased collagen deposition) and
systolic dysfunction when compared to age-matched WT mice. In particular, the load-dependent parameter, ejection
fraction, and the load-independent indices, end-systolic pressure-volume relationship (ESPVR) and Emax, were all significantly
(P,0.05) attenuated in mature GPR552/2 mice. Furthermore, GPR552/2 mice at all ages were characterised by a reduced
contractile reserve. Our findings demonstrate that mice deficient in GPR55 exhibit maladaptive adrenergic signalling, as
evidenced by the reduced contractile reserve. Furthermore, with age these mice are characterised by both significant
adverse ventricular remodelling and systolic dysfunction. Taken together, this may suggest a role for GPR55 in the control of
adrenergic signalling in the heart and potentially a role for this receptor in the pathogenesis of heart failure.
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Introduction
G protein coupled receptor 55 (GPR55) belongs to a group of
rhodopsin-like seven transmembrane/g-protein coupled receptors
and was originally isolated in human striatum [1]. GPR55 has
since been shown to be widely distributed in a variety of cell types
and in the central nervous, gastrointestinal, and cardiovascular
systems, in both humans [2] and rodents [3]. The downstream
signalling mechanisms following activation of GPR55 remain
unclear although activation of Gaq/11 or Ga13 culminating in an
eventual elevation of intracellular calcium (Ca2+) and phosphor-
ylation of extracellular signal-regulated kinase (ERK) and/or
nuclear factor of activated T cells (NFAT) has been implicated [4],
[5], [6]. Furthermore, while the exact physiological/pathophysi-
ological function of GPR55 remains to be determined, studies
have suggested a role in pain, bone development, carcinogenesis,
pregnancy, metabolism (reviewed by [2]), and finally in the control
of cardiac haemodynamics.
In terms of the cardiovascular system, a role for GPR55 was
proposed on the basis of accumulating evidence from a series of
studies investigating the profound haemodynamic (hypotension
and bradycardia) effects of cannabinoid ligands, which were
initially believed to be mediated primarily through the classic
cannabinoid receptors, CB1 and CB2, (reviewed by [7]). However,
combined evidence from studies using mice deficient in either CB1
or CB2 and from experiments employing various pharmacological
agonist/antagonist combinations, have revealed that many can-
nabinoid-induced haemodynamic responses are mediated by non-
CB1/CB2 receptors [8], [9]. Moreover, cannabinoids that have
little or no affinity for the CB1/CB2 receptors have also been
shown to exert cardiovascular effects, further suggesting a role for
additional receptor(s) in mediating these effects [10], [11]. Based
on the findings that some vasoactive cannabinoids (e.g. abnormal
cannabidiol and O-1602) are potent agonists of GPR55 [3], [5],
[12], [13], the latter has been proposed as a possible third
cannabinoid receptor [14], [15]. However, a more recent study
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investigating an array of cannabinoids as possible ligands for
GPR55 demonstrated that only lysophosphatidylinositol (LPI),
rimonabant, and AM251 are agonists for this receptor, and that
neither abnormal cannabidiol nor O-1602 activate GPR55 [16].
Thus, given the incongruous nature of our understanding of the
GPR55 receptor and the relative paucity of literature regarding its
role in cardiovascular physiology we conducted a study using the
previously described homozygous GPR55-deficient (GPR552/2)
mouse [12], [17], to examine the influence of GPR55 on cardiac
physiology/function (assessed via pressure volume loop analysis).
Methods
Breeding and genotyping of GPR55 mice
Heterozygous GPR55 knockout mice were intermated to
produce F1 mice homozygous for the GPR55 mutation
(GPR552/2) and wild-type (WT) littermate controls and geno-
typed as previously described [12]. Both male and female WT and
GPR552/2 were bred and housed in the University of Aberdeen
Medical Research Facility. Animals were maintained at a
temperature of 2162uC, with a 12 h light/dark cycle and with
free access to food and tap water. Animals were obtained on a
daily basis and allowed to acclimatize before commencing the
study. All studies were performed under an appropriate Project
License authorized under the UK Animals (Scientific Procedures)
Act 1986. All in vivo work is reported in accordance with the
ARRIVE guidelines [18].
Measurement of ventricular function
Mice were anaesthetised with a mixture of ketamine
(120 mg kg21; Vetalar, Pfizer, Dublin, Ireland) and xylazine
(16 mg kg21; Rompun, Bayer, Dublin, Ireland) via intraperitoneal
(i.p.) injection and the trachea cannulated to allow artificial
respiration when required. The right jugular vein was cannulated
with flame-stretched Portex polythene tubing (0.58 mm
ID60.96 mm OD; Smiths Medical International Ltd., Hyde,
Kent, UK) for drug administration and the mice ventilated on
room air (130–140 strokes min21 and tidal volume 150–210 mL
calculated based on individual animal weight; Harvard small
animal respiration pump; Edenbridge, Kent, UK). Ventricular
function was measured in mice via pressure volume analysis using
a method adapted from Pacher et al. [19]. Briefly, the chest was
opened, the pericardium removed, the apex of the left ventricle
punctured with a 27 g needle, and a 1.4-Fr pressure conductance
catheter (SPR-839; Millar Instruments, Houston, Texas, US)
inserted into the ventricle to record cardiac function via the
MPVS-Ultra Single Segment Foundation System (Millar Instru-
ments, US). A steel thermistor probe (Fisher Scientific Ltd.,
Loughborough, Leicestershire, UK) was inserted into the rectum
to measure core temperature, which was maintained at 37–38uC
with the aid of a Vetcare heated pad (Harvard Apparatus Ltd.).
Anaesthesia was maintained throughout by administration of 50 ml
25 g21 (b.w.) of the ketamine and xylazine mixture via i.p.
injection every 40 min or as required. After a stabilisation period
of approximately 20 min baseline cardiac function was recorded
and then a bolus dose of dobutamine (10 mg kg21) administered to
mice to examine contractile reserve. To obtain measurements of
load-independent contractility (time varying elastance; Emax) and
the slopes of both the end-systolic pressure-volume relationship
(ESPVR) and end-diastolic pressure-volume relationship
(EDPVR), venous return (left ventricular preload) was varied via
transient occlusion of the inferior vena cava. Finally, to enable
correction of pressure volume loops during data analysis the
parallel conductance (Vp) was calculated via the administration of
a small volume of hypertonic saline (15%; i.v.) to mice. Following
completion of the in vivo protocol, animals were euthanised via an
overdose of anaesthetic and blood collected to allow volume
calibration of the catheter using heparinized blood-filled calibra-
tion cuvettes. Finally, the heart was removed and the ventricular
tissue fixed in 10% formal buffered saline for histological studies.
In vivo experimental protocols
Young male/female (10 week old) WT (n = 15; 8 males & 7
females) and GPR552/2 (n = 15; 8 males & 7 females) mice were
used to investigate the role of GPR55 in the control of basal
cardiac function. As preliminary data had demonstrated that 8
month old GPR552/2 mice had elevated blood pressure
compared to WT mice (unpublished findings from AstraZeneca)
an additional series of experiments was carried out using mature
mice (8 months old; WT (n = 14; 7 males & 7 females) and
GPR552/2 (n = 14; 7 males & 7 females)) to investigate whether
any observed changes in cardiac function were influenced by
advancing age. As there were no gender-related differences in
either cardiac function or structure the data presented represents
the pooled data from both males and females within each group.
Histological assessment of cardiac morphology
For haemotoxylin and eosin (H&E) staining, fixed ventricular
tissue was embedded in paraffin wax (Thermo Scientific) and
5 mm sections cut. Sections were dehydrated through a series of
histosolve (Thermo Scientific) and graded alcohols and incubated
in haematoxylin to stain nuclei, and subsequently incubated in
0.5% acid alcohol, Scott’s tap water substitute, and finally eosin to
stain the remaining cellular material. After staining, sections were
mounted with a xylene substitute mountant (Thermo Scientific)
and covered with a cover slip. Analysis of the tissue was carried out
with the use of a Leica DMLB light microscope (Leica
Microsystems, Milton Keynes, Bucks, UK) at a magnification of
625 for gross morphological measurements and 6400 for
cardiomyocyte analysis and nuclei quantification. For gross
morphology, multiple measurements of the right ventricular free
wall, the interventricular septal wall, and the left ventricular free
wall were made using computerised planimetry (ImageJ software,
National Institute of Health (NIH), Rockville Pike Bethesda, MD).
In addition, left ventricular chamber area was calculated as a
percentage of total left ventricle area. For cardiomyocyte
measurements, the cross-sectional area of 5–10 cardiomyocytes
with a centrally located nucleus and circular shaped cell
membrane was measured in the left ventricular free wall of each
animal using ImageJ. Finally, to detect any changes in myocardial
cellular populations, the number of positively stained nuclei within
10 fields randomly selected from the left ventricle was quantified.
Quantification of cardiac collagen deposition
For Masson Trichrome (MT) staining, paraffin embedded
ventricular sections (5 mm) were dehydrated through a series of
histosolve (Thermo Scientific) and graded alcohols and incubated
in biebrich scarlet-acid fuchsin solution to stain cellular material,
and subsequently incubated in a phosphomolybdic–phosphotungs-
tic acid solution, aniline blue, and finally 1% acetic acid to stain
the collagen fibers. After staining, sections were mounted with a
xylene substitute mountant (Thermo Scientific) and covered with a
cover slip. Photomicrographs (6400) were taken with the use of a
Leica DMLB light microscope (Leica Microsystems, Milton
Keynes, Bucks, UK) and collagen volume fraction (CVF) was
calculated by determining the percentage area of blue (collagen)
stained tissue within 10 fields randomly selected from the left
ventricle using computerised planimetry (ImageJ software,
GPR55 and Cardiac Dysfunction
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National Institute of Health (NIH), Rockville Pike Bethesda, MD).
Briefly, images were converted to RGB stacks, separated into a
montage, and the red channel thresholded to detect the stained
collagen (http://rsbweb.nih.gov/ij/docs/examples/stained-sections/
index.html). For continuity, the same threshold was used on images
from all animals and the measurement of collagen restricted to the
left ventricle to correspond with the functional pressure volume loop
data.
Immunostaining for GPR55
Immunohistochemical staining for GPR55 was performed in
fixed heart sections from all groups. Paraffin embedded myocar-
dial tissue sections were cut (4 mm) and mounted onto polysine
coated slides. Following dehydration and deparaffinization,
antigen retrieval was performed by pressure cooking using Diva
(Biocare, USA). Immunohistochemical staining was carried out
using the Intellipath Immunostainer (Biocare) and involved the
following steps. Endogenous peroxidase activity was blocked via
incubation with Peroxidize 1 (Biocare, USA), followed by
Background sniper (Biocare, USA). The primary antibody,
GRP55-A162T750 (MBL International Corporation) was diluted
1:500 using DaVinci Green Diluent (Biocare, USA) and incubated
on the slides for 1 hour. Sections were then incubated with a two-
step biotin free micro-polymer detection system (MACH3;
Biocare, USA), counterstained with Tachas hematoxylin prior to
incubation with 3,39-diaminobenzidine (Betazoid DAB, Biocare,
USA). Sections were then finally dehydrated and cleared through
a series of graded alcohols and xylene and mounted in Mountex
mounting medium (HistoLAb AB, Sweden). Two negative control
methods were used to verify the specificity of the antibody
reaction. The first negative control was performed by replacing the
MACH3 system with buffer to exclude unspecific binding of the
Figure 1. Expression of GPR55 in ventricular tissue from WT and GPR552/2 mice. Photomicrographs taken at6200 demonstrate positive
staining for GPR55 in ventricular tissue (localised to the cardiomyocytes) from WT mice (A), but not GPR552/2 mice (B).
doi:10.1371/journal.pone.0108999.g001
Table 1. Load-dependent haemodynamic parameters in control (WT) mice and those with a genetic deletion for GPR55
2/2
Young Mice (10 week old) Mature Mice (8 month old)
WT (n=15) GPR552/2 (n = 15) WT (n=14) GPR552/2 (n = 14)
Body weight (g) 2160.5 2360.5 30.560.5 30.760.7
HR (BPM) 39567 42067* 40668 425610
ESP (mmHg) 91.862.2 93.463.5 111.863.5* 101.963.7
EDP (mmHg) 4.560.4 5.160.3 5.260.3 5.360.3
ESV (mL) 11.960.4 13.260.8 16.260.7* 22.760.7#{
EDV (mL) 21.860.8 23.160.6 29.360.8* 35.160.9#{
SV (mL) 11.260.4 11.360.5 15.160.8* 14.260.8#
SW (mmHg*mL) 910676 939666 1377667* 12786103
CO (mL/min) 44306214 47686265 60926382* 59946353
Ea (mmHg/mL) 7.360.7 8.160.6 8.160.5 6.760.4
EF (%) 51.761.9 50.961.7 51.562 40.161.6#{
dP/dtmax (mmHg/s) 78006339 78006486 87606563 83996457
dP/dtmin (mmHg/s) 277736452 272906453 284486578 286436714
Cardiac function is unaffected by age in WT mice, but undergoes a significant deterioration in GPR55 deficient mice. Data is expressed as mean6s.e.m. (n = 14–15).
*P,0.05 vs. WT (Young);
#P,0.05 vs. GPR552/2 (Young);
{P,0.05 vs. WT (Mature).
doi:10.1371/journal.pone.0108999.t001
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GPR55 ).
secondary antibody to the tissue. Secondly, a dilution test was
performed, where the primary antibody was diluted to a
concentration that did not give rise to positive staining.
Photomicrographs of sections were taken at a magnification of
6200 with the use of a Sony progressive 3CCD colour video
camera.
Solutions and chemicals
All chemicals were purchased from either Sigma-Aldrich
(Dorset, UK) or Fisher Scientific UK Ltd. (Loughborough, UK)
unless otherwise stated. Scott’s tap water substitute contained (in
mM): 81 MgSO4.7H2O and 42 NaHCO3.
Statistical analysis
For haemodynamic and morphological data a one-way
ANOVA and bonferroni post-hoc test was used to compare
selected experimental groups. All data was expressed as the
mean6s.e.m and significance was determined as P,0.05.
Results
Effect of gene deletion for GPR55 on baseline cardiac
function in young mice
Positive staining for GPR55 was detected in ventricular tissue
from WT (Figure 1A) but not GPR552/2 mice (Figure 1B).
Furthermore, image analysis revealed diffuse staining for GPR55
throughout the cardiomyocytes, suggestive of a role for this
receptor in the control of contractile function. However, pressure
volume loop analysis revealed that, with the exception of heart rate
(HR), which was significantly elevated in 10 week old GPR552/2
mice, none of the other load-dependent indices of left ventricular
(LV) systolic and diastolic function; end systolic pressure (ESP),
end systolic volume (ESV), stroke volume (SV), cardiac output
(CO), ejection fraction (EF), maximum (dP/dtmax) and minimum
(dP/dtmin) derivatives of pressure, arterial elastance (Ea; an index
of LV afterload and reflective of peripheral vascular resistance),
end diastolic pressure (EDP) and volume (EDV), recorded in this
study differed significantly when compared to 10 week old WT
mice (Table 1). Furthermore, none of the load-independent
Figure 2. Load-independent (ESPVR, EDPVR, and Emax) haemodynamic parameters in both WT and GPR55
2/2 mice. In mature mice
with a genetic deletion for GPR55 (GPR552/2), baseline systolic function, but not diastolic function, was adversely affected. In particular, significant
reductions in both ESPVR (A) and Emax (B) indicate attenuated cardiac contractility, while EDPVR (indicative of relaxation rate) was unaffected (C) in
mature GPR552/2 mice. Data is expressed as mean6s.e.m. (n = 14–15) *P,0.05 vs. WT (Young); #P,0.05 vs. GPR552/2 (Young); {P,0.05 vs. WT
(Mature).
doi:10.1371/journal.pone.0108999.g002
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measurements of LV function, ESPVR, EDPVR, and Emax,
differed significantly between both groups of mice (Figure 2).
Age dependent changes of GPR55 gene deletion on
baseline cardiac function
In terms of load-dependent cardiovascular variables, both
indices of systolic and diastolic function were significantly altered
with age in both WT and GPR552/2 mice (Table 1). In
particular, ESP, ESV, EDV, SV, SW, and CO were all
significantly elevated in mature WT mice compared with young
mice (Table 1), which in part may be due to the increased
circulating blood volume in these larger animals. In contrast, only
SV, EDV, and ESV were significantly increased in mature
GPR552/2 mice, and in terms of the latter two indices they were
also significantly elevated in comparison to age-matched WT
mice. Furthermore, mature GPR552/2 mice also exhibited
compromised systolic function as EF was significantly decreased
in these mice when compared to both young GPR552/2 mice and
age-matched WT controls (P,0.001; Table 1). This emerging
systolic dysfunction appeared to be due to the significant increase
in EDV (P,0.001) recorded in the mature GPR552/2 mice,
which was not accompanied by a sufficient increase in SV (to
maintain EF), when compared to age-matched WT controls
(Table 1). Furthermore, load-independent measurements obtained
during transient occlusion of the inferior vena cava (to alter
preload), demonstrated a significant downward shift in both the
ESPVR slope (P,0.001; Figure 2A) and the time varying elastance
(Emax; P,0.0001; Figure 2B) in the mature GPR55
2/2 mice
indicative of decreased contractility/inotropy. In contrast, the slope
of the EDPVR (indicative of an increase in LV chamber stiffness;
Figure 2C) did not differ significantly between any of the
experimental groups examined and thus load-independent diastolic
function did not appear to be altered following deletion of the
GPR55 gene. Taken together, the changes in both load-dependent
Figure 3. Representative left ventricular pressure volume loops from all experimental groups are included and illustrate the
emerging systolic dysfunction (i.e. downward and rightward shift in the ESPVR curve) associated with mature GPR552/2 mice.
doi:10.1371/journal.pone.0108999.g003
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and load-independent indices of cardiac function observed in the
mature GPR552/2 mice suggest that the emerging systolic
dysfunction appears to be due to the deleterious combination of
both GPR55 gene deletion and advancing age in these animals
(representative pressure volume loops of this cardiac dysfunction are
illustrated in Figure 3).
Morphological measurements of cardiac dimensions revealed
several significant age-related differences in WT mice. In
particular, heart weight:body weight ratio (HW:BW; mg/g),
cardiomyocyte cross-sectional area (CSA), and left ventricular
(LV) wall thickness were all significantly increased in 8 month old
WT mice compared to 10 week old WT mice (all P,0.05;
Table 2). In contrast, HW:BW, LV wall thickness, and nuclei
number were all significantly decreased in the mature GPR552/2
mice compared to age-matched WT mice (both P,0.05) and CSA
was not significantly altered in comparison to young GPR552/2
mice (Table 2). Furthermore, mature GPR552/2 mice were
characterised by significant increases in both interstitial and
perivascular cardiac collagen deposition when compared to both
the younger knockout mice and age-matched WT controls (P,
0.05; Figure 4). While the latter may suggest significant ventricular
remodelling (at least at the level of cardiac extracellular matrix
composition), as this cardiac ‘fibrosis’ was not coupled with a
significant upward shift in the EDPVR slope (Figure 2C) it seems
unlikely that this ventricular remodelling influenced LV compli-
ance and/or diastolic function in these mice. Finally, right
ventricular wall thickness, interventricular septal wall thickness,
and LV chamber area were all unchanged between all four groups
of WT and GPR552/2 mice (Table 2).
Effect of GPR55 gene deletion on contractile reserve in
young and aged mice
Contractile reserve, assessed by the change from baseline
cardiac function in response to the a1/b1-adrenoceptor agonist
dobutamine, was significantly attenuated in both young and
mature GPR552/2 mice (Table 3). In young GPR552/2 mice,
the dobutamine induced increase in dP/dtmax was significantly
attenuated compared to WT mice with a resultant reduction in the
change in SV and consequently CO and EF (all P,0.01; Table 3).
In addition, adrenoceptor mediated changes in dP/dtmin were also
significantly decreased in the young GPR552/2 mice (P,0.01;
Table 3), suggesting an impaired lusitropic effect of dobutamine.
The mature GPR552/2 mice were also characterised by a
decreased response to dobutamine in terms of increases in SV,
CO, EF and dP/dtmax when compared to age-matched controls
(P,0.001; Table 3). These changes occurred concomitant with a
somewhat preserved lusitropic effect in terms of the rate of
relaxation (i.e. dP/dtmin), however EDV did not increase to a
similar extent as that seen in the control group (P,0.001;
Table 3). While mature GPR552/2 were characterised by
reduced contractile reserve, this was no worse than that observed
in young GPR552/2 mice.
Discussion
Our findings demonstrate that genetic deletion of GPR55 in
mice leads to the development of cardiac dysfunction with age and
cardiac decompensation in response to adrenoceptor stimulation.
While basal cardiac function was unaffected in young mice with a
genetic deletion for GPR55, mature GPR552/2 mice, which
would still be considered young adult mice and unlikely to be
affected by senescent heart dysfunction [20], were characterised by
significantly comprised systolic function. In particular, both load-
independent (ESPVR & Emax) and load-dependent (ejection
fraction) indices of systolic function are significantly decreased in
the mature GPR552/2 mice. Furthermore, mature GPR552/2
mice were also characterised by significant myocardial remodel-
ling; including reductions in left ventricular free wall thickness,
HW:BW and ventricular cell number, and increased collagen
deposition. Taken together, these changes are indicative of the
presence of some form of cardiomyopathy (an all-encompassing
term referring to alterations in both cardiac structure and function,
that lead to a deterioration in cardiac function and ultimately
heart failure), and possibly one that possesses several of the features
of dilated cardiomyopathy (DCM) i.e. LV wall thinning,
comprised systolic function, and reduced contractile reserve.
Possible explanations for the emerging systolic dysfunction
observed in the mature GPR552/2 mice may include either
impaired Ca2+ signalling in cardiomyocytes and/or altered central
control of cardiac function. Studies have demonstrated GPR55
induced elevations in intracellular Ca2+ in both endothelial cells
[21], and more recently cardiomyocytes [22]. In the latter study, Yu
et al. [22] demonstrated that LPI applied both extra- and
intracellularly induced elevations in [Ca2+]i in a GPR55 dependent
Table 2. Measurement of ventricular dimensions in WT and GPR552/2 mice.
Young Mice (10 week old) Mature Mice (8 month old)
WT (n=15) GPR552/2 (n =15) WT (n=14) GPR552/2 (n =14)
HW:BW (mg/g) 3.0760.06 3.1960.1 3.9860.06* 3.5960.02{
LV Wall Thickness (mm) 1.6860.04 1.7960.11 1.9260.05* 1.6560.07{
RV Wall Thickness (mm) 0.3960.02 0.3860.04 0.3660.04 0.4060.01
Interventricular Septal Thickness (mm) 1.2560.04 1.2260.06 1.3160.01 1.3560.02
Chamber Area (% of LV) 13.960.9 15.561.3 12.860.7 13.260.8
Cardiomyocyte CSA (mm2) 8969 9468 14565* 14467
Nuclei number (nuclei/mm2) 67266284 64566169 64716393 49836405#{
Ventricular dimensions did not differ significantly between young WT and GPR552/2 mice, however mature GPR552/2 mice were characterised by significant
myocardial remodelling; including a reduction in left ventricular (LV) free wall thickness, myocardial nuclei number, and HW:BW, and increased collagen deposition. Data
is expressed as mean6s.e.m. (n = 14–15).
*P,0.05 vs. WT (Young);
#P,0.05 vs. GPR552/2 (Young);
{P,0.05 vs. WT (Mature).
doi:10.1371/journal.pone.0108999.t002
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manner. Furthermore, these findings led them to suggest that the
receptor was expressed both at the sarcolemma and endo-lysosomal
compartment, which may explain the extensive expression of
GPR55 observed in ventricular tissue in the present study. As the
previous study has demonstrated a role for GPR55 in Ca2+
signalling in the cardiomyocyte [22], it is possible that GPR55 gene
deletion could adversely affect excitation-contraction coupling in
the cardiomyocyte, and consequently the contractile ability of both
the cell and myocardium as a whole. However, as none of the Ca2+
dependent indices of contractility (dP/dtmax, ESPVR or Emax)
differed between young GPR552/2 and WT mice this seems
unlikely.
An alternative explanation may be an affect on the central
control of cardiac contractility. It is well established that in the
early stages of systolic dysfunction, compensatory mechanisms are
initiated to maintain systolic function and meet metabolic
demands, including sympathoexcitation (reviewed by [23]). In
particular, catecholamines acting on b1-adrenoceptors on pace-
maker cells of the sinoatrial node, serve to increase action potential
firing rate and induce a positive chronotropic response [24], [25].
In the present study, mature GPR552/2 mice were not
characterised by positive chronotropy (in an attempt to maintain
systolic function), which may suggest impaired sympathetic control
of the myocardium. In support of this, previous studies have
demonstrated that activation of GPR55 leads to both increased
excitability of dorsal root ganglion neurons [4], and enhanced pre-
synaptic signalling in the hippocampus [26]. Although GPR55
expression in the nucleus tractus solitarius has yet to be
demonstrated, it is possible that GPR55 may have a role in the
regulation of synaptic transmission between preganglionic and
postganglionic sympathetic efferents, and thus deletion of this
GPCR may adversely affect sympathetic outflow. However, as
basal systolic dysfunction appeared to be due to a chronic effect of
GPR55 gene deletion (i.e. only evident at 8 months) and associated
with significant ventricular remodelling it seems unlikely that
GPR55 has a direct role in the control of cardiac function.
In the absence of a direct role for GPR55 in the control of
cardiac contractility it is possible that this GPCR regulates the
activity of another cardiac receptor responsible for regulating
systolic function. Cardiac adrenoceptors, and b-adrenoceptors in
particular, are the predominant GPCR in the heart and the chief
modulators of both cardiac chronotropy and inotropy (reviewed
by [27]). In the present study, all GPR552/2 mice exhibited
significantly attenuated positive inotropic responses to (6)-
dobutamine (an agonist which directly stimulates cardiac adreno-
ceptors) when compared to WT mice, suggesting a pivotal role for
GPR55 in the regulation of adrenoceptor activity in the
myocardium. This proposed maladaptive adrenergic signalling
may in part explain the progressive cardiac dysfunction associated
with these GPR552/2 mice. Accumulating evidence has shown
that chronic stimulation of cardiac b-adrenoceptors activation
leads to receptor phosphorylation via GPCR kinases i.e. bARK1
(desensitization), subsequent internalization of desensitized recep-
tors via b-arrestin (downregulation), a loss of b-adrenoceptor
mediated signalling, and finally the development of systolic heart
failure (reviewed by [28]). Indeed, preservation of b-adrenergic
signalling, via gene delivery of a bARK1 inhibitor, can reverse
and/or prevent the development of cardiac dysfunction [29], [30].
Thus it’s possible that the systolic dysfunction evident in the
mature GPR552/2 mice may be due to the progressive loss of
cardiac adrenoceptors. In line with this it might have been
expected that the impaired positive inotropy to dobutamine
observed in the young GPR552/2 mice would be further
attenuated in the mature knockout mice, however this was not
the case.
A possible explanation for this may involve a1-adrenoceptors, as
although b1-adrenoceptors are thought to be primarily responsible
for catecholamine induced increases in cardiomyocyte contractil-
ity, a1-adrenoceptors have been shown to induce cardiac
contraction [31], [32], [33]. Furthermore, they have previously
been shown to mediate part of the (6)-dobutamine induced
positive inotropy in the rodent heart [34]. Although a1-
adrenoceptor expression in healthy murine and human hearts is
considerably less than that of the b-adrenoceptor subtypes [35], b-
adrenoceptors are downregulated in heart failure whereas a1-
adrenoceptors are not [36], [37]. Thus a1-adrenoceptor-mediated
responses may contribute substantially to the compensatory
positive inotropy in failing hearts.
In addition to altered cardiac function, mature GPR552/2 mice
were also characterised by significant ventricular remodelling
including decreased HW:BW, a thinning of the LV wall, a
reduction in myocardial cell number, and increased collagen
Figure 4. Influence of GPR55 gene deletion on cardiac collagen
deposition. Representative photomicrographs (6400) demonstrating
cardiac collagen deposition in young WT (A), young GPR552/2 (B),
mature WT (C), and mature GPR552/2 (D) mice. Collagen deposition
was significantly increased in the left ventricle of mature GPR552/2
mice (E). Data is expressed as mean6s.e.m. (n = 14–15) #P,0.05 vs.
GPR552/2 (Young); {P,0.05 vs. WT (Mature).
doi:10.1371/journal.pone.0108999.g004
GPR55 and Cardiac Dysfunction
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e108999
deposition. While there is currently no direct evidence for a
functional role for GPR55 in the control of fibroblast activity, a
recent study has demonstrated that this receptor is expressed on
cells, which likely include fibroblasts, in the adventitial layer of
rodent vasculature [38], and that LPI is synthesised by
transformed mouse BALB/3T3 fibroblasts [39], thus it is possible
GPR55 may play a role in fibrogenesis. Indirectly, GPR55 may
regulate fibrogenesis by altering the activity of another GPCR i.e.
CB1, as it has recently been demonstrated that GPR55 can form a
heteromer with CB1 allowing the former to alter the signalling
mechanisms/activity of the latter, and vice versa [40]. Therefore it
is possible that the profibrogenic effect of CB1, previously
documented in an experimental model of doxorubicin-induced
cardiomyopathy [41], may be unimpeded in the mature mice
lacking GPR55 thus resulting in the development of mild cardiac
fibrosis. Finally, if mature GPR552/2 mice are in fact char-
acterised by increased cardiac a1-adrenoceptor activity (as
discussed in the previous section) then this may account for the
increased myocardial collagen deposition as cardiac fibrosis has
previously been demonstrated in mice overexpressing a1-adreno-
ceptors [42].
The observation that mature GPR552/2 mice are characterised
by cardiac fibrosis seems somewhat incongruous with the
significant reductions in both HW:BW and LV wall thickness
(indicative of a ‘lighter’ heart) observed in these animals. Therefore
rather then increased fibrogenesis being the culprit for the
increased cardiac collagen deposition, the latter may simply be
‘increased’ in the face of increased cell death/loss from the heart.
In the present study, the left ventricles of mature GPR552/2 were
characterised by a signficant reduction in stained nuclei indicating
an increase in myocardial cell loss. However, as this data was
acquired from H&E stained tissue, which is not specific for
cardiomyocytes, we cannot conclusively say that all of the cell loss
was due to cardiomyocyte apoptosis and additional studies are
required. Previous work has suggested both anti-inflammatory
[43] and anti-oxidant [44] roles for GPR55, thus loss of the
receptor may lead to a chronic upregulation of both inflammation
and oxidative stress in the mature GPR552/2, both of which are
chief instigators of cardiomyocyte cell death. However as the
present study did not examine either the inflammatory or
oxidative status of these animals these proposed mechanisms
remain to be confirmed.
Exactly how the deletion of the GPR55 gene affects cardiac
adrenoceptor signalling/function in the present study is unclear.
However, accumulating evidence has demonstrated that co-
localised GPCRs, not limited to adrenoceptor subtypes alone
[45], [46], [47], but adrenoceptors and other GPCRs, can interact
and regulate surface expression of each other via a process termed
dimerization (reviewed by [48]). In particular, data from isolated
ventricular cardiomyocytes has demonstrated cross-regulation
between adrenergic and adenosinergic receptors, where stimula-
tion of one inhibited the activity of the other and vice versa [49].
Furthermore, as previously discussed GPR55 can form heteromers
with CB1 enabling both GPCR’s to alter the signalling mecha-
nisms/activity of the other [40]. In heart failure, the crosstalk
between a-adrenoceptors and b-adrenoceptors is well established,
in that expression of the former is elevated in the response to the
downregulation of the latter as a means of sustaining positive
inotropism of the contractile apparatus [50], [51]. While studies
have yet to demonstrate co-expression of GPR55 and adrenocep-
tors within the same cardiomyocytes (as was demonstrated in
murine vascular cells [38]), it is possible that there is some level of
co-localisation in the myocardium that may facilitate crosstalk
between these GPCRs influencing their function/expression,
although this requires investigation. Finally, as the present study
only examined the impact of GPR55 gene deletion on the function
of adrenoceptors, we cannot rule out the possibilty that other
GPCR’s are similarly adversely affected. Furthermore, rather than
GPR55 having a direct effect in terms of modulating other
GPCR’s function it is possible that the absence of this receptor
may result in a more generalised adverse effect i.e. defective G
protein-coupled signalling, culminating in the dysfunction of
numerous GPCRs particularly those involved in stress-sensitive
pathways. Thus the effect of GPR55 gene deletion on other
GPCRs capable of inducing both inotropic and chronotropic
responses should also be investigated in the future.
Table 3. Effect of GPR55 gene deletion on contractile reserve in young (10 week old) and mature (8 month old) mice.
D from baseline 10 week old Mice 8 month old Mice
WT (n=15) GPR552/2 (n = 15) WT (n=14) GPR552/2 (n = 14)
HR (BPM) 11164 9564* 94610 10168
ESP (mmHg) 1965 263* 1562 865
EDP (mmHg) 0.960.5 20.460.3 0.160.3 20.260.3
ESV (mL) 21.360.6 22.560.8 23.860.9 20.460.3{
EDV (mL) 3.760.6 20.160.9 5.561.3 1.660.6{
SV (mL) 5.260.7 1.460.4* 8.960.9* 2.860.5{
SW (mmHg*mL) 571671 98640* 9346104* 294689{
CO (mL/min) 29496354 18106245* 58936443* 15416278{
Ea (mmHg/mL) 2260.5 21.260.3 20.960.2 22.561.4
EF (%) 1462 862* 1461 761{
dP/dtmax (mmHg/s) 67056698 20986306* 59346681 25866738
{
dP/dtmin (mmHg/s) 223896489 28386424* 223846247 212336529
Contractile reserve, assessed by the change from baseline cardiac function in response to the a1/b1-adrenoceptor agonist dobutamine, was significantly attenuated in
both young and mature mice with a gene deletion for GPR55. Data is expressed as mean6s.e.m. (n = 14–15).
*P,0.05 vs. WT (Young);
{P,0.05 vs. WT (Mature).
doi:10.1371/journal.pone.0108999.t003
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Conclusions
The present study has demonstrated that mature GPR552/2
mice are characterised by a progressive ventricular dysfunction.
This intrinsic inability of the heart to maintain systolic function
appears to be due to maladaptive adrenergic signalling, which may
suggest some interplay/crosstalk between GPR55 and adrenocep-
tors and a possible role for GPR55 in the pathogenesis and/or
progression of heart failure.
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